Department of General Surgery, The First People's Hospital of Neijiang, Neijiang, P. R. China.
Department of Hepatobiliary Surgery, Meizhou People's Hospital, Meizhou, Guangdong, P. R. China.
J Cell Physiol. 2019 Nov;234(11):20713-20720. doi: 10.1002/jcp.28677. Epub 2019 Apr 17.
Lysyl oxidase-like 2 (LOXL2) participates in the occurrence and development of digestive system cancers (DSCs). The aim of this study was to determine whether LOXL2 protein could serve as a prognostic biomarker in patients with DSCs. Relevant studies published before October 1, 2018 were identified from a comprehensive literature review in PubMed, Web of Science, and Embase. This meta-analysis was conducted via STATA/SE 14.1 software. Finally, a total of 12 publications and 6 different kinds of DSCs were identified. Meta-analysis indicated that increased expression of LOXL2 protein was significantly correlated with reduced overall survival (hazard ratios [HR]: 1.52; 95% confidence interval [CI]: 1.32-1.72) and worse progression-free survival/disease-free survival (HR: 2.15; 95% CI: 1.48-2.83) in cases with DSCs. In addition, clinicopathological parameters, including tumor invasion, lymph node metastasis, distant metastasis, and clinical stage were significantly related to LOXL2 protein expression in DSCs. High LOXL2 protein expression is significantly associated with worse clinical outcomes in DSCs and its expression level may represent a candidate prognostic biomarker in these cancers.
赖氨酰氧化酶样蛋白 2（LOXL2）参与消化系统癌症（DSC）的发生和发展。本研究旨在确定 LOXL2 蛋白是否可以作为 DSC 患者的预后生物标志物。通过在 PubMed、Web of Science 和 Embase 上进行全面的文献回顾，确定了截至 2018 年 10 月 1 日之前发表的相关研究。本荟萃分析通过 STATA/SE 14.1 软件进行。最终确定了 12 篇出版物和 6 种不同类型的 DSC。荟萃分析表明，LOXL2 蛋白表达增加与 DSC 患者总生存期（风险比 [HR]：1.52；95%置信区间 [CI]：1.32-1.72）和无进展生存期/无病生存期（HR：2.15；95% CI：1.48-2.83）更差显著相关。此外，临床病理参数，包括肿瘤侵袭、淋巴结转移、远处转移和临床分期，与 DSC 中的 LOXL2 蛋白表达显著相关。高 LOXL2 蛋白表达与 DSC 患者的临床结局较差显著相关，其表达水平可能代表这些癌症的候选预后生物标志物。
